IV
IVBXF.US Innovent Biologics Inc
- Market cap
- USD 19.3B
- P/E
- 110.8x
- P/B
- 6.21x
- ROE
- 23.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is IVBXF.US undervalued?
Graham numberThe Graham number of Innovent Biologics Inc cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Innovent Biologics Inc fundamental analysis
No fundamental analysis for Innovent Biologics Inc yet.
Innovent Biologics Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Innovent Biologics Inc
Innovent Biologics, Inc., a biopharmaceutical company, engages in the research and development of antibody and protein medicine products in the People's Republic of China, the United States, Europe, and internationally. The company discovers, develops, manufactures, and commercializes monoclonal antibodies and other drugs for the treatment of oncology, ophthalmology, autoimmune, cardiovascular, and metabolic diseases. Its commercial stage product portfolio includes TYVYT (si…
Full company profileInnovent Biologics Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Innovent Biologics Inc annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 32.1M | 18.5M | 9.48M | 1.05B | 3.84B | 4.27B | 4.56B | 6.21B | 9.42B | 12.7B | 34.0B |
| Gross Profit | 32.1M | 90.0M | 10.8M | 923M | 3.46B | 3.70B | 3.63B | 4.40B | 7.91B | 11.0B | 28.9B |
| Operating Income | -462M | -750M | -1.79B | -1.66B | -557M | -2.70B | -3.12B | -1.68B | -756M | 1.97B | 7.53B |
| EBITDA | -359M | -598M | -5.74B | -1.57B | -705M | -2.37B | -1.75B | -661M | -336M | 2.57B | 8.85B |
| Net Income | -504M | -562M | -5.77B | -1.72B | -998M | -2.73B | -2.18B | -1.03B | -94.6M | 793M | 4.94B |
| EPS | -0.45 | -0.50 | -17 | -1.46 | -0.74 | -1.87 | -1.46 | -0.66 | -0.06 | 0.46 | 2.75 |
| Balance Sheet | |||||||||||
| Total Assets | 2.82B | 2.46B | 6.11B | 7.23B | 11.8B | 16.2B | 17.6B | 20.6B | 21.6B | 37.4B | 41.6B |
| Total Liabilities | 3.77B | 4.08B | 1.92B | 2.47B | 3.06B | 5.91B | 6.86B | 8.10B | 8.48B | 17.2B | 20.9B |
| Shareholders' Equity | -1.38B | -1.94B | 4.19B | 4.76B | 8.78B | 10.3B | 10.7B | 12.5B | 13.1B | 19.4B | 20.7B |
| Cash & Short-term Investments | 1.80B | 1.32B | 4.53B | 4.70B | 8.12B | 9.02B | 9.17B | 11.0B | 7.88B | 18.2B | 20.0B |
| Total Debt | 500M | 510M | 792M | 865M | 1.21B | 2.50B | 3.23B | 3.62B | 2.83B | 2.82B | 2.32B |
| Cash Flow | |||||||||||
| Operating Cash Flow | -363M | -492M | -1.02B | -1.66B | -308M | -2.02B | -1.92B | 148M | 1.29B | 10.0B | 15.0B |
| Capital Expenditure | 58.4M | 91.0M | 313M | 366M | 772M | 1.85B | 1.38B | 1.38B | 1.71B | 683M | 678M |
| Free Cash Flow | -421M | -583M | -1.33B | -2.03B | -1.08B | -3.87B | -3.30B | -1.24B | -418M | 9.32B | 14.3B |
| Ratios | |||||||||||
| ROE | - | - | -137.6% | -36.2% | -11.4% | -26.4% | -20.3% | -8.2% | -0.7% | 4.1% | 23.8% |
| ROA | -17.9% | -22.9% | -94.4% | -23.8% | -8.4% | -16.8% | -12.4% | -5.0% | -0.4% | 2.1% | 11.9% |
| Net Profit Margin | -1,569.4% | -3,033.3% | -60,900.0% | -164.2% | -26.0% | -63.9% | -47.8% | -16.6% | -1.0% | 6.2% | 14.5% |
| Debt to Equity | - | - | 0.19x | 0.18x | 0.14x | 0.24x | 0.30x | 0.29x | 0.22x | 0.15x | 0.11x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Innovent Biologics Inc dividends
Innovent Biologics Inc has not paid dividends in the last 9 fiscal years.
Who owns Innovent Biologics Inc
- Insiders 6.23%
- Institutions 58.67%
- Public & others 35.10%
- Shares outstanding 1.74B
- Free float 1.61B
Innovent Biologics Inc company profile
- Company name
- Innovent Biologics Inc
- Ticker
- IVBXF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 8,754
- Fiscal year end
- December
- Address
- 168 Dongping Street, Suzhou, China, 215123
- Phone
- 86 512 6956 6088
- Website
- innoventbio.com
About Innovent Biologics Inc
Innovent Biologics, Inc., a biopharmaceutical company, engages in the research and development of antibody and protein medicine products in the People's Republic of China, the United States, Europe, and internationally. The company discovers, develops, manufactures, and commercializes monoclonal antibodies and other drugs for the treatment of oncology, ophthalmology, autoimmune, cardiovascular, and metabolic diseases. Its commercial stage product portfolio includes TYVYT (sintilimab injection), BYVASDA (bevacizumab injection), SULINNO (adalimumab injection), HALPRYZA (rituximab injection), PEMAZYRE (pemigatinib), olverembatinib, Cyramza (ramucirumab), Retsevmo (selpercatinib), FUCASO (Equecabtagene Autoleucel), SINTBILO (tafolecimab injection), DUPERT (fulzerasib), DOVBLERON (taletrectinib adipate), Jaypirca (pirtobrutinib), limertinib, SYCUME (teprotumumab N01 injection), mazdutide, PECONDLE (picankibart injection), and TABOSUN(Ipilimumab N01 injection). In addition, it sells and distributes pharmaceutical products; and offers consultation and research and development services. The company was incorporated in 2011 and is headquartered in Suzhou, the People's Republic of China.
Innovent Biologics Inc management
10- Dr. De-Chao Yu Ph.D.Co-Founder, Chairman & CEO · born 1964
- Mr. Hao Xi EdeNon-Executive Director & Fund Managing Partner · born 1959
- Ms. Qian ZhangChief Commercial Officer, General Manager & Executive Director · born 1987
- Ms. Fei You CPAChief Financial Officer · born 1979
- Dr. Kaisong Zhou Ph.D.Chief Operating Officer
- Ms. Zhengwei Song C.F.A.Director of IR & Financial Strategy
- Ms. Cong Ding J.D.General Counsel
- Mr. Blake SalisburySenior Vice President
- Dr. Hui Zhou Ph.D.Chief R&D Officer for Oncology
- Dr. Samuel Suhua Zhang M.B.A., Ph.D.Global Chief Business Officer · born 1968